Vitamin D and Evening Primrose Oil Administration Improve Glycemia and Lipid Profiles in Women with Gestational Diabetes.
Study Goal
The researchers aimed to evaluate the effects of vitamin D and evening primrose oil (EPO) administration on insulin resistance and lipid concentrations in women with gestational diabetes mellitus (GDM).
Results Summary
The study found that combined vitamin D and EPO supplementation significantly improved markers of insulin resistance (e.g., fasting plasma glucose, serum insulin, HOMA-IR) and lipid profiles (e.g., TAG, VLDL, TC, LDL) compared to placebo in women with GDM. No significant effect was observed on serum HDL concentrations.
Population
60 women with gestational diabetes mellitus (GDM).
Effective Dosage
1000 mg EPO daily (combined with 1000 IU vitamin D3).
Duration
6 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D and evening primrose oil (EPO) administration | decrease | fasting plasma glucose | women with GDM | -3.6 ± 7.5 vs. +1.5 ± 11.4 mg/dL | changes in fasting plasma glucose were significantly different from the placebo group | #1 |
vitamin D and evening primrose oil (EPO) administration | decrease | serum insulin concentrations | women with GDM | -2.0 ± 5.3 vs. +4.6 ± 10.7 µIU/mL | changes in serum insulin concentrations were significantly different from the placebo group | #2 |
vitamin D and evening primrose oil (EPO) administration | decrease | HOMA insulin resistance | women with GDM | -0.5 ± 1.1 vs. +1.1 ± 2.5 | changes in homeostasis model of assessment (HOMA) insulin resistance were significantly different from the placebo group | #3 |
vitamin D and evening primrose oil (EPO) administration | decrease | HOMA-B cell function | women with GDM | -7.7 ± 23.3 vs. +17.4 ± 42.9 | changes in HOMA-B cell function were significantly different from the placebo group | #4 |
vitamin D and evening primrose oil (EPO) administration | increase | quantitative insulin sensitivity check index | women with GDM | +0.01 ± 0.02 vs. -0.01 ± 0.02 | changes in the quantitative insulin sensitivity check index were significantly different from the placebo group | #5 |
vitamin D and EPO supplementation | decrease | serum TAG | women with GDM | -20.0 ± 54.3 vs. +34.3 ± 38.2 mg/dL | resulted in significant reductions in serum TAG | #6 |
vitamin D and EPO supplementation | decrease | VLDL | women with GDM | -4.0 ± 10.9 vs. +6.9 ± 7.6 mg/dL | resulted in significant reductions in VLDL | #7 |
vitamin D and EPO supplementation | decrease | TC | women with GDM | -22.1 ± 32.6 vs. +5.3 ± 20.1 mg/dL | resulted in significant reductions in TC | #8 |
vitamin D and EPO supplementation | decrease | LDL concentrations | women with GDM | -18.0 ± 25.5 vs. +1.8 ± 15.7 mg/dL | resulted in significant reductions in LDL concentrations | #9 |
vitamin D and EPO supplementation | decrease | TC/HDL | women with GDM | -0.3 ± 0.4 vs. +0.3 ± 0.5 mg/dL | resulted in significant reductions in TC/HDL | #10 |
vitamin D and EPO supplementation | no change | serum HDL concentrations | women with GDM | - | did not observe any significant effect on serum HDL concentrations | #11 |
UNLABELLED: Limited data are available assessing the effects of vitamin D and evening primrose oil (EPO) administration on markers of insulin resistance and lipid concentrations in gestational diabetes mellitus (GDM). This study was designed to evaluate the effects of vitamin D and EPO administration on insulin resistance and lipid concentrations among women with GDM. In this prospective randomized, double-blind, placebo-controlled clinical trial, 60 participants with GDM were divided into 2 groups of either 1000 IU vitamin D3 and 1000 mg EPO or placebo for 6 weeks. At the beginning and end of the study, fasting blood samples were obtained from the participants to measure related variables. After 6 weeks of intervention, changes in fasting plasma glucose (-3.6 ± 7.5 vs. +1.5 ± 11.4 mg/dL, P = 0.04), serum insulin concentrations (-2.0 ± 5.3 vs. +4.6 ± 10.7 µIU/mL, P = 0.004), homeostasis model of assessment (HOMA) insulin resistance (-0.5 ± 1.1 vs. +1.1 ± 2.5, P = 0.003), HOMA-B cell function (-7.7 ± 23.3 vs. +17.4 ± 42.9, P = 0.007) and the quantitative insulin sensitivity check index (+0.01 ± 0.02 vs. -0.01 ± 0.02, P = 0.007) in the vitamin D plus EPO group were significantly different from the placebo group. In addition, compared with the placebo, vitamin D and EPO supplementation resulted in significant reductions in serum TAG (-20.0 ± 54.3 vs. +34.3 ± 38.2 mg/dL, P < 0.001), VLDL (-4.0 ± 10.9 vs. +6.9 ± 7.6 mg/dL, P < 0.001), TC (-22.1 ± 32.6 vs. +5.3 ± 20.1 mg/dL, P < 0.001), LDL concentrations (-18.0 ± 25.5 vs. +1.8 ± 15.7 mg/dL, P = 0.001) and TC/HDL (-0.3 ± 0.4 vs. +0.3 ± 0.5 mg/dL, P < 0.001). We did not observe any significant effect of vitamin D and EPO supplementation on serum HDL concentrations. CLINICAL TRIAL REGISTRATION NUMBER: http://www.irct.ir : IRCT201509115623N52.